RESUMO
A series of amino acid monoester prodrugs of floxuridine was synthesized and evaluated for the improvement of oral bioavailability and the feasibility of target drug delivery via oligopeptide transporters. All floxuridine 5'-amino acid monoester prodrugs exhibited PEPT1 affinity, with inhibition coefficients of Gly-Sar uptake (IC50) ranging from 0.7 - 2.3 mM in Caco-2 and 2.0 - 4.8 mM in AsPC-1 cells, while that of floxuridine was 7.3 mM and 6.3 mM, respectively. Caco-2 membrane permeabilities of floxuridine prodrugs (1.01 - 5.31 x 10(-6 )cm/sec) and floxuridine (0.48 x 10(-6 )cm/sec) were much higher than that of 5-FU (0.038 x 10(-6) cm/sec). MDCK cells stably transfected with the human oligopeptide transporter PEPT1 (MDCK/hPEPT1) exhibited enhanced cell growth inhibition in the presence of the prodrugs. This prodrug strategy offers great potential, not only for increased drug absorption but also for improved tumor selectivity and drug efficacy.
Assuntos
Aminoácidos/farmacologia , Antimetabólitos Antineoplásicos/farmacologia , Proliferação de Células/efeitos dos fármacos , Floxuridina/farmacologia , Floxuridina/farmacocinética , Pró-Fármacos/farmacologia , Pró-Fármacos/farmacocinética , Simportadores/metabolismo , Absorção/efeitos dos fármacos , Aminoácidos/síntese química , Aminoácidos/farmacocinética , Animais , Antimetabólitos Antineoplásicos/síntese química , Células CACO-2 , Cães , Sistemas de Liberação de Medicamentos , Ésteres , Inibidores do Crescimento/farmacocinética , Inibidores do Crescimento/farmacologia , Humanos , Transportador 1 de Peptídeos , Pró-Fármacos/síntese química , Simportadores/biossíntese , Simportadores/genéticaRESUMO
The human intestinal oligopeptide transporter (PEPT1) facilitates the absorption of dipeptides, tripeptides, and many peptidomimetic drugs. In this study, a large number of peptides were selected to investigate the structural features required for PEPT1 transport. Binding affinity was determined in a Gly-Sar uptake inhibition assay, whereas functional transport was ranked in a membrane depolarization assay. Although most of the peptides tested could bind to PEPT1, not all were substrates. As expected, single amino acids and tetrapeptides could not bind to or be transported by PEPT1. Dipeptide transport was influenced by charge, hydrophobicity, size, and side chain flexibility. The extent of transport was variable, and unexpectedly, some dipeptides were not substrates of PEPT1. These included dipeptides with two positive charges or extreme bulk in either position 1 or 2. Our results identify key features required for PEPT1 transport in contrast to most previously described pharmacophores, which are based on the inhibition of transport of a known substrate.
Assuntos
Dipeptídeos/farmacocinética , Simportadores/fisiologia , Animais , Sítios de Ligação , Transporte Biológico , Linhagem Celular , Dipeptídeos/química , Dipeptídeos/metabolismo , Cães , Eletricidade , Interações Hidrofóbicas e Hidrofílicas , Modelos Moleculares , Transportador 1 de Peptídeos , Prolina/química , Ligação Proteica , Conformação Proteica , Relação Estrutura-Atividade , Simportadores/metabolismoRESUMO
Floxuridine is a clinically proven anticancer agent in the treatment of metastatic colon carcinomas and hepatic metastases. However, prodrug strategies may be necessary to improve its physiochemical properties and selectivity and to reduce undesirable toxicity effects. Previous studies with amino acid ester prodrugs of nucleoside drugs targeted to the PEPT1 transporter coupled with recent findings of the functional expression of the PEPT1 oligopeptide transporter in pancreatic adenocarcinoma cell lines suggest the potential of PEPT1 as therapeutic targets for cancer treatment. In this report, we show the feasibility of achieving enhanced transport and selective antiproliferative action of amino acid ester prodrugs of floxuridine in cell systems overexpressing PEPT1. All prodrugs exhibited affinity for PEPT1 (IC50, 1.1-2.3 mmol/L). However, only the prolyl and lysyl prodrugs exhibited enhanced uptake (2- to 8-fold) with HeLa/PEPT1 cells compared with HeLa cells, suggesting that the aspartyl prodrugs are PEPT1 inhibitors. The selective growth inhibition of Madine-Darby canine kidney (MDCK)/PEPT1 cells over MDCK cells by the prodrugs was consistent with the extent of their PEPT1-mediated transport. All ester prodrugs hydrolyzed to floxuridine fastest in Caco-2 cell and MDCK homogenates and slower in human plasma and were most chemically stable in pH 6.0 buffer. Prolyl and lysyl prodrugs were relatively less stable compared with aspartyl prodrugs in buffers and in cell homogenates. The results suggest that optimal design for targeted delivery would be possible by combining both stability and transport characteristics afforded by the promoiety.
Assuntos
Antimetabólitos Antineoplásicos/farmacologia , Floxuridina/farmacologia , Pró-Fármacos/química , Simportadores/biossíntese , Aminoácidos/química , Animais , Células CACO-2 , Linhagem Celular , Linhagem Celular Tumoral , Proliferação de Células , Cromatografia Líquida de Alta Pressão , Cães , Células HeLa , Humanos , Concentração de Íons de Hidrogênio , Hidrólise , Concentração Inibidora 50 , Lisina/química , Modelos Químicos , Metástase Neoplásica , Nucleosídeos/química , Oligopeptídeos/química , Neoplasias Pancreáticas/tratamento farmacológico , Transportador 1 de Peptídeos , Pró-Fármacos/farmacologia , Prolina/química , Simportadores/metabolismo , Fatores de TempoRESUMO
Amino acid ester prodrugs of 2-bromo-5,6-dichloro-1-(beta-d-ribofuranosyl)benzimidazole (BDCRB) were synthesized and evaluated for their affinity for hPEPT1, an intestinal oligopeptide transporter. Assays of competitive inhibition of [(3)H]glycylsarcosine (Gly-Sar) uptake in HeLa/hPEPT1 cells by the amino acid ester prodrugs of BDCRB suggested their 2- to 4-fold higher affinity for hPEPT1 compared to BDCRB. Further, promoieties with hydrophobic side chains and l-configuration were preferred by the hPEPT1 transporter.
Assuntos
Aminoácidos/síntese química , Antivirais/síntese química , Benzimidazóis/síntese química , Pró-Fármacos/síntese química , Ribonucleosídeos/síntese química , Simportadores/metabolismo , Aminoácidos/química , Aminoácidos/farmacologia , Antivirais/química , Antivirais/farmacologia , Benzimidazóis/química , Benzimidazóis/farmacologia , Dipeptídeos/antagonistas & inibidores , Dipeptídeos/metabolismo , Ésteres , Células HeLa , Humanos , Transportador 1 de Peptídeos , Pró-Fármacos/química , Pró-Fármacos/farmacologia , Ribonucleosídeos/química , Ribonucleosídeos/farmacologia , Estereoisomerismo , Relação Estrutura-AtividadeRESUMO
A novel N-terminal-to-side chain cyclic dynorphin A analogue lacking the basic N-terminus was designed based on Ac[Lys(2),Trp(3),Trp(4),d-Ala(8)]dynorphin A-(1-11)NH(2) (Wan et al. J. Med. Chem. 1999, 42, 3011-3013). cyclo(N,5)[Trp(3),Trp(4),Glu(5)]dynorphin A-(1-11)NH(2) showed similar kappa opioid receptor affinity (K(i) = 27 nM) and selectivity (K(i) ratio (kappa/mu/delta) = 1/12/330) to the linear peptide and antagonized dynorphin A-(1-13)NH(2) at kappa opioid receptors. This is the first opioid peptide cyclized through the N-terminus that retains high opioid receptor affinity.
Assuntos
Dinorfinas/síntese química , Peptídeos Cíclicos/síntese química , Receptores Opioides kappa/antagonistas & inibidores , Animais , Células CHO , Cricetinae , AMP Cíclico/antagonistas & inibidores , AMP Cíclico/biossíntese , Dinorfinas/química , Dinorfinas/farmacologia , Ligantes , Peptídeos Cíclicos/química , Peptídeos Cíclicos/farmacologiaRESUMO
cyclo[d-Asp(2),Dap(5)]Dyn A-(1-13)NH(2) (Dap, 2,3-diaminopropionic acid; Dyn A, dynorphin A), synthesized previously in our laboratory, showed sub-nanomolar affinity for kappa opioid receptors and potent agonist activity in the guinea pig ileum assay (Arttamangkul et al., J. Med. Chem. 1995, 38, 2410-2417). Various modifications were made in position 3 of cyclo[d-Asp(2),Dap(5)]Dyn A-(1-11)NH(2) that could influence the opioid receptor affinity, selectivity, and/or efficacy of this peptide. An optimized orthogonal synthetic strategy was developed for the synthesis of these cyclic peptides in which the final peptides could be cleaved from the solid support with trifluoroacetic acid. Substitutions of Gly(3) by Ala, d-Ala, Trp, and d-Trp in cyclo[d-Asp(2),Dap(5)]Dyn A-(1-11)NH(2) and its linear counterpart [d-Asp(2),Dap(5)]Dyn A-(1-11)NH(2) were generally well tolerated by both kappa and micro opioid receptors. Despite differences in the size and stereochemistry of the substitutions, most of the peptides (except for cyclo[d-Asp(2),Pro(3),Dap(5)]Dyn A-(1-11)NH(2) and [d-Asp(2),d-Ala(3), Dap(5)]Dyn A-(1-11)NH(2)) exhibited low nanomolar affinity for both kappa (K(i) = 0.21 to 2.2 nM) and micro (K(i) = 0.22 to 7.27 nM) opioid receptors. All of the 3-substituted cyclic and linear analogues synthesized showed reduced affinity for delta opioid receptors. Incorporation of d-Ala at position 3 of cyclo[d-Asp(2),Dap(5)]Dyn A-(1-11)NH(2) exhibited 2-fold higher kappa opioid receptor affinity and 16-fold higher selectivity for kappa over micro opioid receptors than the parent cyclic peptide. In contrast, substitution of Ala at position 3 resulted in an analogue with 2.4-fold lower affinity and very low preference for kappa over micro opioid receptors. The Trp and d-Trp cyclic and linear analogues exhibited similar nanomolar affinities for kappa opioid receptors. cyclo[d-Asp(2),Pro(3),Dap(5)]Dyn A-(1-11)NH(2) showed the largest decreases in affinity for all three opioid receptors compared to the parent cyclic peptide. Except for cyclo[d-Asp(2), Pro(3),Dap(5)]Dyn A-(1-11)NH(2), which was a partial agonist, all of the cyclic peptides exhibited full agonist activity in the adenylyl cyclase assay using cloned kappa opioid receptors.
Assuntos
Dinorfinas/síntese química , Peptídeos Cíclicos/síntese química , Receptores Opioides/efeitos dos fármacos , Adenilil Ciclases/metabolismo , Animais , Células CHO , Cromatografia Líquida de Alta Pressão , Cricetinae , Dinorfinas/química , Dinorfinas/farmacologia , Peptídeos Cíclicos/química , Peptídeos Cíclicos/farmacologia , Ensaio Radioligante , Receptores Opioides/metabolismo , Receptores Opioides delta/efeitos dos fármacos , Receptores Opioides delta/metabolismo , Receptores Opioides kappa/efeitos dos fármacos , Receptores Opioides kappa/metabolismo , Receptores Opioides mu/efeitos dos fármacos , Receptores Opioides mu/metabolismo , Relação Estrutura-AtividadeRESUMO
Phenylalanine at position 4 of the peptide dynorphin A (Dyn A) is an important residue for opioid receptor affinity and activity, but there is very little information available on the structure-activity relationships or conformational preference of this residue for interaction with kappa-opioid receptors. Based on the hypothesis that the spatial orientation of the aromatic ring at position 4 of Dyn A is important for opioid receptor affinity and selectivity, a series of Dyn A analogues with various Phe derivatives substituted at position 4 were synthesized and evaluated for their opioid receptor affinity and activity. The L- and D-Homophe4 (homophenylalanine) analogues of [D-Ala8]Dyn A-(1-11)NH2 were compared to the (R)- and (S)-Atc4 (2-aminotetralin-2-carboxylic acid) derivatives (Aldrich et al. Chirality 2001, 13, 125-129). [l-Homophe4,D-Ala8]Dyn A-(1-11)NH2 exhibited higher kappa-opioid receptor affinity than the D-Homophe4 isomer, while [(R)-Atc4,D-Ala8]Dyn A-(1-11)NH2 exhibited higher kappa-opioid receptor affinity than the (S)-Atc4 isomer. Comparing the structure of Atc to those of Phe and Homophe, these results suggest that the Atc isomers are functioning more as constrained Homophe rather than Phe analogues in these Dyn A derivatives. The higher kappa-opioid receptor affinity of the (R)-Atc4 analogue suggests that Phe4 of Dyn A most likely adopts a gauche (-) or trans conformation in the kappa-opioid receptor binding site. Comparison of [D-Ala8]Dyn A-(1-11)NH2 derivatives containing Aic4 (2-aminoindan-2-carboxylic acid) and Tic4 (1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) with the peptides containing their acyclic counterparts alpha-MePhe4 and N-MePhe4, respectively, suggest that the loss in opioid receptor affinity seen for the Aic4 and Tic4 analogues is probably due to an improper orientation of the aromatic ring in these residues. Most of the analogues in this series showed much lower affinity for delta-opioid receptors than the parent peptide, suggesting that kappa- and delta-opioid receptors have distinct binding pockets for the residue at position 4 of Dyn A. All of the analogues with high affinity for kappa-opioid receptors exhibited full agonist activity in the adenylyl cyclase assay using cloned kappa-opioid receptors, indicating that changes in the position or orientation of the phenyl ring in this residue did not alter the ability of the peptides to activate the receptor.
Assuntos
Alanina/química , Dinorfinas/química , Dinorfinas/metabolismo , Fenilalanina/análogos & derivados , Fenilalanina/metabolismo , Adenilil Ciclases/efeitos dos fármacos , Adenilil Ciclases/metabolismo , Sequência de Aminoácidos , Animais , Sítios de Ligação , Células CHO , Clonagem Molecular , Colforsina/antagonistas & inibidores , Colforsina/farmacologia , Cricetinae , Dinorfinas/síntese química , Dinorfinas/farmacologia , Isomerismo , Modelos Moleculares , Fenilalanina/farmacologia , Conformação Proteica , Ensaio Radioligante , Ratos , Receptores Opioides/genética , Receptores Opioides/metabolismo , Especificidade por SubstratoRESUMO
Prodrugs are biologically inactive agents that upon biotransformation in vivo result in active drug molecules. Since prodrugs might alter the tissue distribution, efficacy and the toxicity of the parent drug, prodrug design should be considered at the early stages of preclinical development. In this regard, natural and synthetic amino acids offer wide structural diversity and physicochemical properties. This review covers the use of amino acid prodrugs to improve poor solubility, poor permeability, sustained release, intravenous delivery, drug targeting, and metabolic stability of the parent drug. In addition, practical considerations and challenges associated with the development of amino acid prodrugs are also covered.
Assuntos
Aminoácidos/química , Pró-Fármacos/química , Aminoácidos/administração & dosagem , Animais , Sistemas de Liberação de Medicamentos , Desenho de Fármacos , Humanos , Pró-Fármacos/administração & dosagemRESUMO
The expression levels of genes involved in drug and nutrient absorption were evaluated in the Madin-Darby Canine Kidney (MDCK) in vitro drug absorption model. MDCK cells were grown on plastic surfaces (for 3 days) or on Transwell® membranes (for 3, 5, 7, and 9 days). The expression profile of genes including ABC transporters, SLC transporters, and cytochrome P450 (CYP) enzymes was determined using the Affymetrix® Canine GeneChip®. Expression of genes whose probe sets passed a stringent confirmation process was examined. Expression of a few transporter (MDR1, PEPT1 and PEPT2) genes in MDCK cells was confirmed by RT-PCR. The overall gene expression profile was strongly influenced by the type of support the cells were grown on. After 3 days of growth, expression of 28% of the genes was statistically different (1.5-fold cutoff, p < 0.05) between the cells grown on plastic and Transwell® membranes. When cells were differentiated on Transwell® membranes, large changes in gene expression profile were observed during the early stages, which then stabilized after 5-7 days. Only a small number of genes encoding drug absorption related SLC, ABC, and CYP were detected in MDCK cells, and most of them exhibited low hybridization signals. Results from this study provide valuable reference information on endogenous gene expression in MDCK cells that could assist in design of drug-transporter and/or drug-enzyme interaction studies, and help interpret the contributions of various transporters and metabolic enzymes in studies with MDCK cells.
RESUMO
PURPOSE: To determine the bioactivation and uptake of prolidase-targeted proline prodrugs of melphalan in six cancer cell lines with variable prolidase expression and to evaluate prolidase-dependence of prodrug cytotoxicity in the cell lines compared to that of the parent drug, melphalan. MATERIALS AND METHODS: Hydrolysis, cell uptake, and cell proliferation studies of melphalan and the L: - and D: -proline prodrugs of melphalan, prophalan-L: and prophalan-D: , respectively, were conducted in the cancer cell lines using established procedures. RESULTS: The bioactivation of prophalan-L: in the cancer cell lines exhibited high correlation with their prolidase expression levels (r (2) = 0.86). There were no significant differences in uptake of melphalan and its prodrugs. The cytotoxicity of prophalan-L: (GI(50)) in cancer cells also showed high correlation with prolidase expression (r (2) = 0.88), while prophalan-D: was ineffective at comparable concentrations. A prolidase targeting index (ratio of melphalan to prophalan-L: cytotoxicity normalized to their uptake) was computed and showed high correlation with prolidase expression (r (2) = 0.82). CONCLUSIONS: The data corroborates the specificity of prophalan-L: activation by prolidase as well as prolidase-targeted cytotoxicity of prophalan-L: in cancer cell lines. Hence, prophalan-L: , a stable prodrug of melphalan, exhibits potential for efficiently targeting melanoma with reduced systemic toxicity.
Assuntos
Antineoplásicos Alquilantes/metabolismo , Dipeptidases/metabolismo , Melanoma/metabolismo , Melfalan/metabolismo , Pró-Fármacos/metabolismo , Prolina/metabolismo , Antineoplásicos Alquilantes/química , Antineoplásicos Alquilantes/farmacologia , Transporte Biológico , Biotransformação , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Clorambucila/metabolismo , Dipeptidases/antagonistas & inibidores , Dipeptidases/genética , Relação Dose-Resposta a Droga , Regulação Enzimológica da Expressão Gênica/efeitos dos fármacos , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Humanos , Hidrólise , Concentração Inibidora 50 , Melanoma/enzimologia , Melanoma/genética , Melanoma/patologia , Melfalan/análogos & derivados , Melfalan/química , Melfalan/farmacologia , Pró-Fármacos/química , Pró-Fármacos/farmacologia , Prolina/análogos & derivados , Prolina/química , Prolina/farmacologia , Inibidores de Proteases/farmacologia , RNA Mensageiro/metabolismo , EstereoisomerismoRESUMO
Bioinformatics tools such as Perl, Visual Basic, Cluster, and TreeView were used to analyze public gene expression databases in order to identify potential enzyme targets for prodrug strategies. The analyses indicated that prolidase might be a desirable enzyme target based on its differential expression in melanoma cancer cell lines and its high substrate specificity for dipeptides containing proline at the carboxy terminus. RT-PCR expression of prolidase and hydrolytic activity against N-glycyl-l-proline (GLY-PRO), a standard substrate of prolidase, determined in tumor cell lines, exhibited a high correlation (r(2) = 0.95). These results suggest the possibility of targeting prolidase with prodrugs of anticancer agents for enhanced selectivity. The feasibility of such a scenario was tested by (a) synthesizing prodrugs of melphalan that comprised linkage of the carboxy terminus of the l-phenylalanine moiety of melphalan to the N-terminus of l and d stereoisomers of proline and (b) determining their bioconversion and antiproliferative activities in SK-MEL-5 cells, a melanoma cancer cell line with high expression levels of prolidase. The results of hydrolysis studies of the l- and d-proline prodrugs of melphalan, designated as prophalan-l and prophalan-d, respectively, indicated a approximately 7-fold higher rate of activation of prophalan-l compared to prophalan-d in SK-MEL-5 cell homogenates. Prophalan-l exhibited cytotoxicity (GI(50) = 74.8 microM) comparable to that of melphalan (GI(50) = 57.0 microM) in SK-MEL-5 cells while prophalan-d was ineffective, suggesting that prolidase-specific activation to the parent drug may be essential for cytotoxic action. Thus, melphalan prodrugs such as prophalan-l that are cleavable by prolidase offer the potential for enhanced selectivity by facilitating cytotoxic activity only in cells overexpressing prolidase.
Assuntos
Dipeptidases/uso terapêutico , Desenho de Fármacos , Melanoma/tratamento farmacológico , Melfalan/análogos & derivados , Pró-Fármacos/uso terapêutico , Prolina/análogos & derivados , Prolina/química , Sequência de Aminoácidos , Antineoplásicos , Células CACO-2 , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Colorimetria , Estudos de Viabilidade , Humanos , Células K562 , Melfalan/síntese química , Melfalan/química , Melfalan/metabolismo , Melfalan/uso terapêutico , Análise de Sequência com Séries de Oligonucleotídeos , Pró-Fármacos/síntese química , Pró-Fármacos/química , Pró-Fármacos/metabolismo , Prolina/síntese química , Prolina/metabolismo , Prolina/uso terapêutico , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Especificidade por SubstratoRESUMO
Gemcitabine, a clinically effective nucleoside anticancer agent, is a polar drug with low membrane permeability and is administered intravenously. Further, extensive degradation of gemcitabine by cytidine deaminase to an inactive metabolite in the liver affects its activity adversely. Thus, strategies that provide both enhanced transport and high metabolic bioevasion would potentially lead to oral alternatives that may be clinically useful. The objective of this study was to evaluate whether amino acid ester prodrugs of gemcitabine would (a) facilitate transport across intestinal membranes or across cells that express hPEPT1 and (b) provide resistance to deamination by cytidine deaminase. 3'-Monoester, 5'-monoester, and 3',5'-diester prodrugs of gemcitabine utilizing aliphatic (L-valine, D-valine, and L-isoleucine) and aromatic (L-phenylalanine and D-phenylalanine) amino acids as promoieties were synthesized and evaluated for their affinity and direct hPEPT1-mediated transport in HeLa/hPEPT1 cells. All prodrugs exhibited enhanced affinity (IC(50): 0.14-0.16 mM) for the transporter. However, only the 5'-L-valyl and 5'-L-isoleucyl monoester prodrugs exhibited (a) increased uptake (11.25- and 5.64-fold, respectively) in HeLa/hPEPT1 cells compared to HeLa cells and (b) chemical stability in buffers, that were comparable to valacyclovir, a commercially marketed oral amino acid ester prodrug. The widely disparate enzymatic bioconversion profiles of the 5'-L-valyl and 5'-L-isoleucyl prodrugs in Caco-2 cell homogenates along with their significant resistance to deamination by cytidine deaminase suggest that the disposition of gemcitabine following oral administration would be controlled by the rate of bioconversion following transport across the intestinal epithelial membrane. The combined results also suggest that it may be possible to modulate these characteristics by the choice of the amino acid promoiety.
Assuntos
Aminoácidos/farmacologia , Antineoplásicos/farmacologia , Desoxicitidina/análogos & derivados , Pró-Fármacos/química , Simportadores/química , Aminoácidos/química , Antineoplásicos/química , Transporte Biológico , Células CACO-2 , Linhagem Celular Tumoral , Cromatografia Líquida de Alta Pressão , Citidina Desaminase/química , Citidina Desaminase/metabolismo , Desoxicitidina/farmacocinética , Desoxicitidina/farmacologia , Dipeptídeos/farmacocinética , Ensaios de Seleção de Medicamentos Antitumorais/métodos , Células HeLa , Humanos , Hidrólise , Concentração Inibidora 50 , Transportador 1 de Peptídeos , Peptídeos/química , GencitabinaRESUMO
Novel N-terminus-to-side-chain cyclic analogs of the opioid peptide dynorphin (Dyn) A-(1-11)NH(2) were prepared that retain the basicity of the N-terminal amine and restrict the backbone conformation around the important Tyr(1) residue. Cyclic peptides were synthesized in which the N-terminal amine and the N(epsilon)-amine of a Lys at position 3 or 5 were attached to the alpha-carbon and carbonyl of an acetyl group, respectively. Several synthetic strategies were explored with detailed analysis of the side reactions in order to obtain the desired cyclic peptides. One of the side reactions observed involved premature loss of the N-terminal 9-fluorenylmethoxycarbonyl (Fmoc) group during the neutralization step following deprotection of the Mtt (4-methyltrityl) protecting group from the side chain of Lys. The successful strategy involved the synthesis of the linear peptide up through Gly(2) and functionalization through the N(epsilon)-amine of Lys. A linear N-terminal alkylated analog was prepared by alkylation of the peptide on the resin with an equimolar amount of bromoacetamide, followed by treatment of the peptide with Fmoc-OSu prior to cleavage from the resin to facilitate separation by reversed phase high performance liquid chromatography of unreacted peptide from the desired alkylated product. The novel N-terminal cyclic Dyn A analogs and the linear analog were evaluated for their opioid receptor affinities. These peptides exhibited large losses in affinity for opioid receptors; the low affinity of the linear N-terminal alkylated peptide suggested that the alpha-acetamide group on the N-terminal amine resulted in unfavorable interactions with opioid receptors.
Assuntos
Dinorfinas/síntese química , Animais , Células CHO , Cricetinae , Dinorfinas/química , Dinorfinas/metabolismo , Peptídeos Cíclicos/química , Peptídeos Cíclicos/metabolismo , Receptores Opioides/química , Receptores Opioides/metabolismoRESUMO
Biphenyl hydrolase-like protein (BPHL, NCBI accession number NP_004323) is a novel human serine hydrolase recently identified as a human valacyclovirase, catalyzing the hydrolytic activation of the antiviral prodrugs valacyclovir and valganciclovir. The substrate specificity of BPHL was investigated with a series of amino acid ester prodrugs of the therapeutic nucleoside analogues: acyclovir, zidovudine, floxuridine, 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl) benzimidazole, and gemcitabine. The hydrolysis of typical esterase and aminopeptidase substrates by BPHL was also investigated. The results indicate that the substrate specificity of BPHL is largely determined by the amino acid acyl promoiety, and is less sensitive to the nucleoside parent drugs. For all nucleoside parent drugs, BPHL preferred the hydrophobic amino acids valine, phenylalanine, and proline over the charged amino acids lysine and aspartic acid. The position and monoester or diester form of the prodrug were also important, with BPHL exhibiting higher affinity for the 5'-esters than for the 3'-esters and the 3',5'-diesters irrespective of amino acid type. Further, the presence of the 3'-amino acid ester considerably reduced the hydrolysis rate of the 5'-amino acid ester functionality. BPHL exhibited stereoselectivity with an L/D specificity ratio of 32 for 5'-valyl floxuridine and 1.5 for 5'-phenylalanyl floxuridine. The substrate specificity suggests that the substrate-binding pocket of BPHL has a hydrophobic acyl binding site which can accommodate the positively charged alpha-amino group, while having an alcohol leaving group binding site that can accommodate nucleoside analogues with a relatively generous spatial allowance. In conclusion, BPHL catalyzes the hydrolytic activation of amino acid esters of a broad range of therapeutic nucleoside analogues in addition to valacyclovir and valganciclovir and has considerable potential for utilization as an activation target for design of antiviral and anticancer nucleoside analogue prodrugs.
Assuntos
Aciclovir/análogos & derivados , Aciclovir/farmacologia , Aciclovir/farmacocinética , Antivirais/farmacocinética , Hidrolases de Éster Carboxílico/metabolismo , Ganciclovir/análogos & derivados , Ganciclovir/farmacocinética , Pró-Fármacos/farmacologia , Pró-Fármacos/farmacocinética , Valina/análogos & derivados , Valina/farmacologia , Valina/farmacocinética , Sequência de Aminoácidos , Antivirais/farmacologia , Hidrolases de Éster Carboxílico/química , Hidrolases de Éster Carboxílico/genética , Clonagem Molecular , Desenho de Fármacos , Ativação Enzimática , Escherichia coli , Ganciclovir/farmacologia , Variação Genética , Humanos , Cinética , Dados de Sequência Molecular , Proteínas Recombinantes de Fusão/química , Proteínas Recombinantes de Fusão/metabolismo , Alinhamento de Sequência , Homologia de Sequência de Aminoácidos , Especificidade por Substrato , Valaciclovir , ValganciclovirRESUMO
We have cloned and functionally expressed a sodium-dependent human nucleoside transporter, hCNT2, from a CNS cancer cell line U251. Our cDNA clone of hCNT2 had the same predicted amino acid sequence as the previously cloned hCNT2 transporter. Of the several cell lines studied, the best hCNT2 transport function was obtained when transiently expressed in U251 cells. Na(+)-dependent uptake of [3H]inosine in U251 cells transiently expressing hCNT2 was 50-fold greater than that in non-transfected cells, and uptake in Na(+)-containing medium was approximately 30-fold higher than that at Na(+)-free condition. The hCNT2 displayed saturable uptake of [3H]inosine with K(m) of 12.8 microM and V(max) of 6.66 pmol/mg protein/5 min. Uptake of [3H]inosine was significantly inhibited by the purine nucleoside drugs dideoxyinosine and cladribine, but not by acyclic nucleosides including acyclovir, ganciclovir, and their prodrugs valacyclovir and valganciclovir. This indicates that the closed ribose ring is important for binding of nucleoside drugs to hCNT2. Among several pyrimidine nucleosides, hCNT2 favorably interacted with the uridine analogue floxuridine. Interestingly, we found that benzimidazole analogues, including maribavir, 5,6-dichloro-2-bromo-1-beta-D-ribofuranosylbenzimidazole (BDCRB), and 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB), were strong inhibitors of inosine transport, even though they have a significantly different heterocycle structure compared to a typical purine ring. As measured by GeneChip arrays, mRNA expression of hCNT2 in human duodenum was 15-fold greater than that of hCNT1 or hENT2. Further, the rCNT2 expression in rat duodenum was 20-fold higher than rCNT1, rENT1 or rENT2. This suggests that hCNT2 (and rCNT2) may have a significant role in uptake of nucleoside drugs from the intestine and is a potential transporter target for the development of nucleoside and nucleoside-mimetic drugs.
Assuntos
Duodeno/metabolismo , Proteínas de Membrana Transportadoras/metabolismo , Animais , Transporte Biológico/efeitos dos fármacos , Clonagem Molecular , Humanos , Inosina/metabolismo , Cinética , Proteínas de Membrana Transportadoras/genética , Nucleosídeos de Purina/química , Nucleosídeos de Purina/farmacologia , Nucleosídeos de Pirimidina/química , Nucleosídeos de Pirimidina/farmacologia , Ratos , Transcrição Gênica , Células Tumorais CultivadasRESUMO
PURPOSE: To synthesize amino acid ester prodrugs of floxuridine (FUdR) and to investigate the effects of structure, stereochemistry, and site of esterification of promoiety on the rates of hydrolysis of these prodrugs in Caco-2 cell homogenates. METHODS: Amino acid ester prodrugs of FUdR were synthesized using established procedures. The kinetics of hydrolysis of prodrugs was evaluated in human adenocarcinoma cell line (Caco-2) homogenates and pH 7.4 phosphate buffer. RESULTS: 3'-Monoester, 5'-monoester, and 3',5'-diester prodrugs of FUdR utilizing proline, L-valine, D-valine, L-phenylalanine, and D-phenylalanine as promoieties were synthesized and characterized. In Caco-2 cell homogenates, the L-amino acid ester prodrugs hydrolyzed 10 to 75 times faster than the corresponding D-amino acid ester prodrugs. Pro and Phe ester prodrugs hydrolyzed much faster (3- to 30-fold) than the corresponding Val ester prodrugs. Further, the 5'-monoester prodrugs hydrolyzed significantly faster (3-fold) than the 3',5'-diester prodrugs. CONCLUSIONS: Novel amino acid ester prodrugs of FUdR were successfully synthesized. The results presented here clearly demonstrate that the rate of FUdR prodrug activation in Caco-2 cell homogenates is affected by the structure, stereochemistry, and site of esterification of the promoiety. Finally, the 5'-Val and 5'-Phe monoesters exhibited desirable characteristics such as good solution stability and relatively fast enzymatic conversion rates.
Assuntos
Aminoácidos/química , Antineoplásicos/síntese química , Floxuridina/química , Pró-Fármacos/síntese química , Aminoácidos/metabolismo , Antineoplásicos/química , Antineoplásicos/metabolismo , Soluções Tampão , Células CACO-2 , Cromatografia Líquida de Alta Pressão , Ésteres , Floxuridina/metabolismo , Humanos , Hidrólise , Estrutura Molecular , Pró-Fármacos/química , Pró-Fármacos/metabolismo , Estereoisomerismo , Relação Estrutura-AtividadeRESUMO
PepT1 is a transporter of proven pharmaceutical utility for enhancing oral absorption. A high-throughput, robust functional assay, capable of distinguishing PepT1 binders from substrates, allowing identification and/or prediction of drug candidate activation was developed. An MDCK epithelial cell line was transfected with rPepT1. The high level of stable rPepT1 expression that was achieved enabled development of a miniaturized PepT1 assay in a 96-well format, which could be scaled to 384 wells. The assay is based on measurement of membrane depolarization resulting from the cotransport of protons and PepT1 substrates. Membrane potential changes are tracked with a voltage-sensitive fluorescent indicator. Control (mock-transfected) cells are used to determine nonspecific membrane potential changes. A variety of fluorescent dyes were tested during initial assay design, including intracellular pH and membrane potential indicators. A membrane potential indicator was chosen because of its superior performance. Upon PepT1 activation with glycylsarcosine, dose-dependent membrane depolarization was observed with an EC50 of 0.49 mM. Maximum depolarization was dependent on the level of PepT1 expression. Testing of 38 known PepT1 substrates, binders, and nonbinders demonstrated that this assay accurately distinguished substrates from binders and from nonbinders. Initial validation of this novel assay indicates that it is sensitive and robust, and can distinguish between transporter substrates and antagonists. This important distinction has been previously achieved only with lower-throughput assays. This assay might also be used to determine substrate potency and establish a high-quality data set for PepT1 SAR modeling.